Nan H Lin

Address:

616 Ashford Rd, Wilmington, DE 19803

VIN:

1FTFW1R65BFC70735

Make:

FORD

Model:

F-150

Year:

2011

US Patent:

6898568, May 24, 2005

Filed:

Jul 13, 2001

Appl. No.:

09/904999

Inventors:

Kai Wa Ng - Singapore, SG
Nan Sheng Lin - Fremont CA, US
Jing Zheng Ouyang - San Jose CA, US

Assignee:

Innomedia PTE LTD - Singapore

International Classification:

G10L017/00

US Classification:

704246, 704209, 704270, 704273

Abstract:

A identity of a remote speaker is verified by receiving compressed audio formants from a remote Internet telephony client and comparing the compressed audio formants with sample compressed audio formants known to represent the person the remote speaker purports to be. The compressed audio formants include energy and pitch data characterizing the residue of the speaker uttering a predetermined pass phrase and a plurality of formant coefficients characterizing the resonance of the speaker.

US Patent:

7243112, Jul 10, 2007

Filed:

Jun 14, 2002

Appl. No.:

10/480567

Inventors:

Kunbin Qu - Foster City CA, US
Nan Lin - Foster City CA, US
Yanmei Lu - Foster City CA, US
Donald G. Payan - Hillsborough CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

G06F 17/30

US Classification:

7071041, 707102, 707103 R, 707 3

Abstract:

This invention provides an advanced platform for the analysis of biological data that emphasizes pathway mapping and relationship inference based upon data acquired from multiple diverse sources. The platform employs a bioinformatic system that integrates data from the diverse sources, connecting related genes and proteins and inferring biological functions in the context of global cellular processes.

US Patent:

20180296579, Oct 18, 2018

Filed:

Apr 18, 2016

Appl. No.:

15/568206

Inventors:

- South San Francisco CA, US
Nan Lin - Redwood City CA, US
Rajinder Singh - Belmont CA, US

International Classification:

A61K 31/675
A61K 45/06
C12Q 1/6886

Abstract:

Disclosed are methods of treating an ibrutinib-resistant disease in a mammal with a compound of Formula (I): wherein R is described herein. In certain embodiments, a compound of Formula (I) inhibits the activity of a variant Btk, providing a method of treating ibrutinib-resistant diseases, such as ibrutinib-resistant lymphoma.

US Patent:

20180051006, Feb 22, 2018

Filed:

Aug 15, 2017

Appl. No.:

15/677809

Inventors:

- South San Francisco CA, US
Xiang Xu - Foster City CA, US
Sarkiz Issakani - Redwood City CA, US
Rajinder Singh - Belmont CA, US
Yasumichi Hitoshi - Brisbane CA, US
Matthew Duncton - San Bruno CA, US
Nan Lin - Foster City CA, US

International Classification:

C07D 403/04
C07D 235/26
C07D 403/14
C07D 403/12

Abstract:

Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structureand pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R, R, R, R, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.